Is Adding E2 to P4 Luteal Support In High Responder Long Gn-RH Agonist ICSI Cycles Detrimental to Outcome? RCT
Primary Purpose
IVF, Infertility
Status
Completed
Phase
Not Applicable
Locations
Egypt
Study Type
Interventional
Intervention
estradiol plus progesterone 100 mg IM injection
Progesterone IM of 100 mg
Sponsored by
About this trial
This is an interventional treatment trial for IVF focused on measuring luteal support, high responder, ICSI, cycle outcome
Eligibility Criteria
Inclusion criteria
- age<40 years,
- first ICSI cycle,
- third day FSH< 10 mIU/mL,
- serum E2 level on day of hCG administration <4,000 pg/mL,
- number of ova obtained >15
Exclusion Criteria:
- age 40 years or more,
- basal FSH 10 mIU/mL or more ,
- eggs retrieved 15 or less ,
- E2 level on day of hCG administration 4000 or more pg/ mL or more,
- repeat ICSI , need for PGD, presence of myoma , hydrosalpinx (unless disconnected)
Sites / Locations
- Mansoura Integrated fertility center
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
estradiole - progesterone arm
Progesterone only arm
Arm Description
Cases are given estradiole valerate 2mg 3 times /day from day of ovum pick up until the time of pregnancy test two weeks together with daily IM injection of 100 progesterone starting . Single intramuscular 0.1 mg decapeptyl are given on day of transfer
Patient are given 100 mg progesterone daily starting on day of pickup plus single dose of decapeptyl 0.1 mg on day of embryo transfer
Outcomes
Primary Outcome Measures
cycle pregnancy rate
pregnancy rate per started cycle
Secondary Outcome Measures
implantation rate, multiple pregnancy rate, ongoing pregnancy rate ,live birth rate
implantation rate,multible pregnancy rate, abortion rate
Full Information
NCT ID
NCT01790282
First Posted
February 8, 2013
Last Updated
June 14, 2022
Sponsor
Mansoura Integrated Fertility Center
1. Study Identification
Unique Protocol Identification Number
NCT01790282
Brief Title
Is Adding E2 to P4 Luteal Support In High Responder Long Gn-RH Agonist ICSI Cycles Detrimental to Outcome? RCT
Official Title
Is E2 Luteal Support in High Responder Long Gn-RH Agonist ICSI Cycles Detrimental to Cycle Outcome ? A Randomized Clinical Trial
Study Type
Interventional
2. Study Status
Record Verification Date
June 2022
Overall Recruitment Status
Completed
Study Start Date
March 2013 (undefined)
Primary Completion Date
December 2014 (Actual)
Study Completion Date
March 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Mansoura Integrated Fertility Center
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Study if supporting luteal phase of high responder (high egg production or high Estradiol level) long Gn_Rh agonist protocol ICSI/IVF cycle by combined Estradiol and progesterone impairs or improves outcome in terms of pregnancy and implanation rates.
Detailed Description
The role of estradiol (E2) luteal support is still debated after more than a decade of use. Two recent met analyses (Gelbaya et al 2008) &(Jee et al 2010)( ) has shown that the addition of E2 to P4 for luteal phase support in IVF/ICSI cycles has no beneficial effect on pregnancy rates. However they commented that the data in the literature are, limited and heterogeneous, precluding the extraction of clear and definite conclusions. Previous met analysis ( Pritts and Atwood 2002 ) and an update (Fatemi et al 2007 ) and subsequent randomized trials ( Ghanem et al 2009 , Var et al 2011 ) reported beneficial effects of adding E2 to luteal P4 support. Recent retrospective studies have shown that high response in terms of excess egg production ( >15 . ) and or high E2 (Chen et al 2007,Kyrou et al 2009, Sunkara 2011 ) are detrimental to cycle outcome. This prospective randomized trial aims to study whether adding E2 to P4 luteal support in high ovarian responders is detrimental to cycle outcome or not
--------------- Gelbaya TA, KyrgiouM, Tsoumpou I, Nardo LG. The use of estradiol for luteal phase support in in vitro fertilization/intracytoplasmic sperminjec- tion cycles: a systematic review and meta-analysis. Fertil Steril 2008;90: 2116-25.
Jee BC, Suh CS, Kim SH, Kim YB, Moon SY. Effects of estradiol supplementation during the luteal phase of in vitro fertilization cycles: a meta-analysis Fertil Steril. 2010 Feb;93(2):428-36
Pritts EA, Atwood AK. Luteal phase support in infertility treatment: a meta-analysis of randomized trials. Hum Reprod 2002;17:2287-99 Fatemi HM, Popovic-Todorovic B, Papanikolaou E, Donoso P,Devroey P. An update of luteal phase support in stimulated IVF cycles.Hum Reprod Update 2007;13:581.
Ghanem M E., Ehab E. Sadek, Elboghdady L. A.. Helal A S, Gamal Anas, Eldiasty A Bakre N I., Houssen M .The effect of luteal phase support protocol on cycle outcome and luteal phase hormone profile in long agonist protocol intracytoplasmic sperm injection cycles: a randomized clinical trial , Fertility and Sterility 2009 92: 486-493
Var T, Tonguc EA, Doğanay M, Gulerman C, Gungor T, Mollamahmutoglu L. A comparison of the effects of three different luteal phase support protocols on in vitro fertilization outcomes: a randomized clinical trial. Fertil Steril. 2011 Mar 1;95(3):985-9.
van der Gaast, Eijkemans JB, de Boer EJ, Burger CW , van Leeuwen FE, Fauser BCJM , and Macklon NS Optimum number of oocytes for a successful first IVF treatment cycle Reproductive BioMedicine Online 2006 ; 13: 476-480
Sunkara SK, Rittenberg V, Raine-Fenning N, Bhattacharya S, Zamora J, Coomarasamy A. Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles. Hum Reprod 2011; 26: 1768-1774
Chen QJ, Sun XX, Li L, Gao XH, Wu Y, Gemzell-Danielsson K, Cheng LN Effects of ovarian high response on implantation and pregnancy outcome during controlled ovarian hyperstimulation (with GnRH agonist and rFSH). Acta Obstet Gynecol Scand. 2007;86:849-54 Kyrou D., Popovic-Todorovic B., Fatemi H.M1, Bourgain C, Haentjens P., Van Landuyt L., and. Devroey P Does the estradiol level on the day of human chorionic gonadotrophin administration have an impact on pregnancy rates in patients treated with rec-FSH/GnRH antagonist? Hum Reprod 2009, 2902-2909,
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
IVF, Infertility
Keywords
luteal support, high responder, ICSI, cycle outcome
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
220 (Actual)
8. Arms, Groups, and Interventions
Arm Title
estradiole - progesterone arm
Arm Type
Experimental
Arm Description
Cases are given estradiole valerate 2mg 3 times /day from day of ovum pick up until the time of pregnancy test two weeks together with daily IM injection of 100 progesterone starting . Single intramuscular 0.1 mg decapeptyl are given on day of transfer
Arm Title
Progesterone only arm
Arm Type
Active Comparator
Arm Description
Patient are given 100 mg progesterone daily starting on day of pickup plus single dose of decapeptyl 0.1 mg on day of embryo transfer
Intervention Type
Drug
Intervention Name(s)
estradiol plus progesterone 100 mg IM injection
Other Intervention Name(s)
estradiole valerate 2mg,, Prontogest 100 mg
Intervention Description
estradile valaerate 2mg plus progesterone 100 mg/day support arm :E2 valerate 2mg three times /day are given to the arm cases plus P4 100 IM/day for 14 days starting on day of ovum pickup and single IM injection of 0.1 mg decapeptyl on day of ET
Intervention Type
Drug
Intervention Name(s)
Progesterone IM of 100 mg
Other Intervention Name(s)
prontogest 100 mg ampoles
Intervention Description
Starting on day of ovum pickup ICSI cases are given prontogest 100 mg IM /day plus single dose dose of treptorline 0.1mg is given sc on day of embryo transfer
Primary Outcome Measure Information:
Title
cycle pregnancy rate
Description
pregnancy rate per started cycle
Time Frame
6 weeks
Secondary Outcome Measure Information:
Title
implantation rate, multiple pregnancy rate, ongoing pregnancy rate ,live birth rate
Description
implantation rate,multible pregnancy rate, abortion rate
Time Frame
6 weeks
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
39 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria
age<40 years,
first ICSI cycle,
third day FSH< 10 mIU/mL,
serum E2 level on day of hCG administration <4,000 pg/mL,
number of ova obtained >15
Exclusion Criteria:
age 40 years or more,
basal FSH 10 mIU/mL or more ,
eggs retrieved 15 or less ,
E2 level on day of hCG administration 4000 or more pg/ mL or more,
repeat ICSI , need for PGD, presence of myoma , hydrosalpinx (unless disconnected)
Facility Information:
Facility Name
Mansoura Integrated fertility center
City
Mansoura
State/Province
Dekahlia
Country
Egypt
12. IPD Sharing Statement
Citations:
PubMed Identifier
18178194
Citation
Gelbaya TA, Kyrgiou M, Tsoumpou I, Nardo LG. The use of estradiol for luteal phase support in in vitro fertilization/intracytoplasmic sperm injection cycles: a systematic review and meta-analysis. Fertil Steril. 2008 Dec;90(6):2116-25. doi: 10.1016/j.fertnstert.2007.10.053. Epub 2008 Jan 7.
Results Reference
background
PubMed Identifier
21558332
Citation
Sunkara SK, Rittenberg V, Raine-Fenning N, Bhattacharya S, Zamora J, Coomarasamy A. Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles. Hum Reprod. 2011 Jul;26(7):1768-74. doi: 10.1093/humrep/der106. Epub 2011 May 10.
Results Reference
background
Learn more about this trial
Is Adding E2 to P4 Luteal Support In High Responder Long Gn-RH Agonist ICSI Cycles Detrimental to Outcome? RCT
We'll reach out to this number within 24 hrs